Journal of Contemporary Brachytherapy

Abstract

5/2020 vol. 12
Original paper

Interventional radiotherapy as exclusive treatment for primary nasal vestibule cancer: single-institution experience

  1. U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Roma, Italy
  2. Istituto di Radiologia, Università Cattolica del Sacro Cuore, Roma, Italy
  3. Divisione di Otorinolaringoiatria, Azienda Ospedaliero Universitaria, Sassari, Italy
  4. U.O.C. Otorinolaringoiatria, Dipartimento Scienze dell’Invecchiamento, Neurologiche, Ortopediche e della testa collo, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Roma, Italy
  5. Dipartimento di Radioterapia, Fondazione Ricerca e Cura Giovanni Paolo II, Università Cattolica del Sacro Cuore, Campobasso, Italy
  6. Istituto di Otorinolaringoiatria, Università Cattolica del Sacro Cuore, Roma, Italy
  7. Otorinolaringoiatria, Università degli studi di Sassari, Sassari, Italy
J Contemp Brachytherapy 2020; 12, 5: 413–419
Online publish date: 2020/10/30
View full text

Introduction

The aim of this paper was to evaluate treatment outcomes following interventional radiotherapy (brachytherapy – BT) for nasal vestibule cancer.

Material and methods

Considering histological diagnosis and staging, a multidisciplinary tumor board indicated an exclusive interventional radiotherapy for all patients. Plastic tubes were placed mainly with interstitial approach. The total dose was 44 Gy in 14 fractions, 3 Gy/fraction (except for the first and last fractions, 4 Gy), 2 fractions per day (b.i.d.), 5 days a week. Inclusion criteria for this analysis were: patients affected by squamous cell carcinoma with follow-up more than 6 months.

Results

20 patients with primary nasal vestibule cancer were treated with IRT from May 2012 to June 2019. We excluded 4 patients due to follow-up less than 6 months and 2 patients affected by basal cell carcinoma. In total, 14 consecutive previously untreated patients were considered for definitive analysis, median age was 67.5 (range, 51-83) years, median follow-up was 53 (range, 6-84) months. All patients followed the protocol except one, who received a total dose of 42 Gy in 12 fractions, 3 Gy per 6 fractions, and 4 Gy per 6 fractions. Local control at 12, 24, and 36 months was 85.7%. Overall survival at 12 months was 92.3%, at 24 months was 76.9%, and at 36 months was 69.2%. Staging system proposed by Wang was statistically significant on local control (LC), disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). Excellent cosmetic results were observed.

Conclusions

This study confirms that interventional radiotherapy could be considered as a definitive treatment in nasal vestibule cancer with excellent oncological and cosmetic outcomes.

Share
without publication fees